Estrogen News and Research

Latest Estrogen News and Research

Women with menopausal transition experience cognitive difficulties

The memory problems that many women experience in their 40s and 50s as they approach and go through menopause are both real and appear to be most acute during the early period of post menopause. That is the conclusion of a study which appears today in the journal Menopause.

4 Jan 2013

Genetic differences in enzyme CYP2D6 play a key role in effectiveness of tamoxifen for breast cancer

For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer will recur.

27 Dec 2012

Few alcohol-related story ideas from The Methodist Hospital

The holidays are a time to consume -- food, gifts, and spirits. Here are a few alcohol-related story ideas from The Methodist Hospital. Because alcohol's effects on human physiology are complex, advice about is often contradictory.

20 Dec 2012

Osteoporosis screening: an interview with Professor Cyrus Cooper

Osteoporosis is defined as a reduction in bone mass coupled with micro-architectural deterioration of bone tissue which predisposes to fractures. Osteoporosis manifests through an increased risk of fracture, and age-related fractures are a major public health problem.

17 Dec 2012

Paternal exposure to cocaine can impair gene expression and behavior in their offspring

Research from the Perelman School of Medicine at the University of Pennsylvania and Massachusetts General Hospital (MGH) reveals that sons of male rats exposed to cocaine are resistant to the rewarding effects of the drug, suggesting that cocaine-induced changes in physiology are passed down from father to son.

17 Dec 2012

Study describes new, paradoxical characteristics of HER2-negative breast cancer

A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer.

15 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

TSEC strategy can benefit postmenopausal women

Investigators at Wake Forest Baptist Medical Center have concluded research on a new postmenopausal hormone therapy that shows promise as an effective treatment for menopausal symptoms and the prevention of osteoporosis without increasing the risk for heart disease or breast cancer.

13 Dec 2012

Delayed childbearing may protect against triple-negative breast cancer

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.

12 Dec 2012

Emotion helps us recognize words quicker and more accurately straight away

Does the emotion in our voice have a lasting effect? According to Annett Schirmer and colleagues from the National University of Singapore, emotion helps us recognize words quicker and more accurately straight away.

12 Dec 2012

Study identifies KNDy neurons as a likely control switch of hot flushes

Hot flushes affect millions of people, and not just women. Yet, it is still unclear what causes the episodes of temperature discomfort, often accompanied by profuse sweating.

12 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

ATLAS holds up 10-year tamoxifen regime

Results from the ATLAS study indicate that women with estrogen receptor-positive breast cancer should consider taking tamoxifen for up to 10 years after diagnosis.

10 Dec 2012

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

10 Dec 2012

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

7 Dec 2012

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics.

6 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

Estrogen News and Research

Latest Estrogen News and Research

Women with menopausal transition experience cognitive difficulties

Genetic differences in enzyme CYP2D6 play a key role in effectiveness of tamoxifen for breast cancer

Few alcohol-related story ideas from The Methodist Hospital

Osteoporosis screening: an interview with Professor Cyrus Cooper

Paternal exposure to cocaine can impair gene expression and behavior in their offspring

Study describes new, paradoxical characteristics of HER2-negative breast cancer

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

TSEC strategy can benefit postmenopausal women

Delayed childbearing may protect against triple-negative breast cancer

Emotion helps us recognize words quicker and more accurately straight away

Study identifies KNDy neurons as a likely control switch of hot flushes

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

ATLAS holds up 10-year tamoxifen regime

Most triple-negative breast cancer patients have multiple genetic mutations after chemo treatment

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Researchers investigate GPER receptor as possible new drug target for breast cancer

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Estrogen News and Research

Latest Estrogen News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in